False positives in cancer epidemiology

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 1, 2013, Pages 11-15

  McLaughlin, Joseph K ^a   Tarone, Robert E ^a  

^a INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CARCINOGENICITY; DISEASE CLASSIFICATION; FALSE POSITIVE RESULT; HUMAN; PRIORITY JOURNAL;

BIAS (EPIDEMIOLOGY); CARCINOGENS; EPIDEMIOLOGIC STUDIES; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INTERNATIONAL AGENCIES; MALE; NEEDS ASSESSMENT; NEOPLASMS;

EID: 84872129324     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0995     Document Type: Article

References (43)

1. Demetriou C, Straif K, Vineis P. From testing to estimation: the problem of false positives in the context of carcinogen evaluation in the IARC Monographs. Cancer Epidemiol Biomarkers Prev 2012;21:1272-81.
2. Phillips CV. Publication bias in situ. BMC Med Res Methodol 2004;4:20.
3. Ioannidis JPA. Why most discovered true associations are inflated. Epidemiology 2008;19:640-8.
4. Boffetta P, McLaughlin JK, La Vecchia C, Tarone RE, Lipworth L, Blot WJ. False-positive results in cancer epidemiology: a plea for epistemological modesty. J Natl Cancer Inst 2008;100:988-95.
5. Kabat GC. Hyping health risks: environmental hazards in daily life and the science of epidemiology. New York: Columbia University Press; 2008. p. 5, 9-11.
6. Kuran T, Sunstein CR. Availability cascades and risk regulation. Stanford Law Rev 1999;51:683-768.
7. Ioannidis JPA. Why most published research findings are false. PLoS Med 2005;2:e124.
8. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72.
9. Ioannidis JPA, Tarone RE, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 2011;22:450-6.
10. Ioannidis JPA, Tarone RE, McLaughlin JK. X-WAS, traditional epidemiology, and policy action. Epidemiology 2011;22:467-8.
11. Blair A, Saracci R, Vineis P, Cocco P, Forastiere F, Grandjean P, et al. Epidemiology, public health, and the rhetoric of false positives. Environ Health Perspect 2009;117:1809-13.
12. Brown R. Group processes. 2nd ed. Malden, MA: Blackwell Publishing; 2000. p. 167-224.
13. Sunstein CR. Deliberating groups versus prediction markets (or Hayek's challenge to Habermas). Episteme 2006;3:192-213.
14. Erren TC. IARC's plea for traditional 'expert' working groups-a recipe for problems? Int J Epidemiol 2011;40:1727-8.
15. McLauglin JK, Boffetta P, La Vecchia C, Lipworth L, Blot WJ, Tarone RE. Problems with IARC's 'expert' working groups. Int J Epidemiol 2011;40:1728-9.
16. Boffetta P, McLaughlin JK, La Vecchia C, Tarone RE, Lipworth L, Blot WJ. A further plea for adherence to the principles underlying science in general and the epidemiologic enterprise in particular. Int J Epidemiol 2009;38:678-9.
17. Kabat G. Behind the World Health Organization's "cancerous" pronouncement on cell phones. Forbes; 2011 [cited 2012 Jul 31]. Available from: http://www.forbes.com/sites/realspin/2011/08/23/world-health-organization- cancerous-cell-phones/.
18. 1 mice (feed study). Bethesda, MD: National Toxicology Program; 1982 Mar. Technical Report No. 214.
19. Je Y, Giovannucci E. Coffee consumption and risk of endometrial cancer: findings from a large up-to-date meta-analysis. Int J Cancer 2012;131:1700-10.
20. Bravi F, Bosetti C, Tavani A, La Vecchia C. Coffee drinking and hepatocellular carcinoma: an update. Hepatology 2009;50:1317-8.
21. Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, et al. Risk factors for hepatocellular carcinoma-current status and perspectives. Asian Pacific J Cancer Prev 2012;13:743-52.
22. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer 2011;11:96.
23. Swerdlow AJ, Feychting M, Green AC, Kheifets L, Savitz DA International Commission for Non-Ionizing Radiation Protection Standing Committee on Epidemiology. Mobile phones, brain tumours and the interphone study: where are we now? Environ Health Perspect 2011;119:1534-8.
24. Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J. Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden 1974-2003. J Natl Cancer Inst 2009;101:1721-4.
25. de Vocht F, Burstyn I, Cherrie JW. Time trends (1998-2007) in brain cancer incidence rates in relation to mobile phone use in England. Bioelectromagnetics 2011;32:334-9.
26. Ahlbom A, Feychting M. Mobile telephones and brain tumours. BMJ 2011;343:d6605.
27. Little MP, Rajaramn P, Curtis RE, Devesa SS, Inskip PD, Check DP, et al.Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 2012;344:e1147.
28. Shu X, Ahlbom A, Feychting M. Incidence trends of malignant parotid gland tumors in Swedish and Nordic adults 1970 to 2009. Epidemiology 2012;23:766-7.
29. Hardell L, Mild KH, Påhlson A, Hallquist A. Ionizing radiation, cellular telephones and the risk for brain tumors. Eur J Cancer Prev 2001;10:523-9.
30. Hardell L, Carlberg M, Mild KH. Re-analysis of risk for gliomas in relation to mobile telephone use: comparison with the results of the Interphone international case-control study. Int J Epidemiol 2011;40:1126-8.
31. Bosetti C, McLaughlin JK, Tarone RE, Pira E, La Vecchia C. Formaldehyde and cancer risk: a quantitative review of cohort studies through 2006. Ann Oncol 2008;19:29-43.
32. Boffetta P, Fryzek JP, Mandel JS. Occupational exposure to beryllium and cancer risk: a review of the epidemiologic evidence. Crit Rev Toxicol 2012;42:107-18.
33. Tarone RE, McLaughlin JK. Re: "Mortality from solid cancers among workers in formaldehyde industries". Am J Epidemiol 2005;161:1089-91.
34. Marsh GM, Youk AO. Reevaluation of mortality risks from nasopharyngeal cancer in the formaldehyde cohort study of the National Cancer Institute. Regul Toxicol Pharmacol 2005;42:275-83.
35. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality from solid cancers among workers in formaldehyde industries. Am J Epidemiol 2004;159:1117-30.
36. Edling C, Järvholm B, Andersson L, Axelson O. Mortality and cancer incidence among workers in an abrasive manufacturing industry. Br J Ind Med 1987;44:57-9.
37. Bertazzi PA, Pesatori A, Guercilena S, Consonni D, Zocchetti C. Carcinogenic risk for resin producers exposed to formaldehyde: extension of follow-up. Med Lav 1989;80:111-22.
38. Andjelkovich DA, Janszen DB, Brown MH, Richardson RB, Miller FJ. Mortality of iron foundry workers: IV. Analysis of a subcohort exposed to formaldehyde. J Occup Environ Med 1995;37:826-37.
39. Coggon D, Harris EC, Poole J, Palmer KT. Extended follow-up of a cohort of British chemical workers exposed to formaldehyde. J Natl Cancer Inst 2003;95:1608-15.
40. Pinkerton LE, Hein MJ, Stayner LT. Mortality among a cohort of garment workers exposed to formaldehyde: and update. Occup Environ Med 2004;61:193-200.
41. Marsh GM, Youk AO, Buchanich JM, Erdal S, Esmen NA. Work in metal industry and nasopharyngeal cancer mortality among formaldehyde-exposed workers. Regul Toxicol Pharmacol 2007;48:308-19.
42. IARC Working Group. IARC monographs on the evaluation of carcinogenic risks to humans, vol 100F: chemical agents and related occupations. Lyon, France: IARC Press; 2012. p. 401-35.
43. Hauptmann M, Stewart PA, Lubin JH, Beane Freeman LE, Hornung RW, Herrick RF, et al. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. J Natl Cancer Inst 2009;101:1696-1708.